Ascent Pharmaceuticals Inc FDA Inspection Record

FEI 3009518416 · Inspections, Form 483s, warning letters and import refusals

Ascent Pharmaceuticals Inc is an FDA-registered facility (FEI 3009518416) located in Central Islip, NY, US. Registered operations: ANALYSIS; LABEL; MANUFACTURE; PACK. RegDataLab tracks 9 FDA inspections at this facility.

What FDA found at this site

Latest inspection
Aug 9, 2024: Voluntary Action Indicated (VAI)
Inspections on record
9 (6 VAI, 3 NAI)
Last OAI inspection
None on record
Warning letters
None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
Recalls as the recalling firm
3, latest Nov 19, 2021

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Newest first. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Aug 9, 2024Voluntary Action Indicated (VAI)No citations listed
Sep 15, 2022Voluntary Action Indicated (VAI)Failure to comply with REMS Implementation System (FDCA 505-1(f)(4))
Oct 13, 2020Voluntary Action Indicated (VAI)No citations listed
Nov 7, 2018No Action Indicated (NAI)No citations listed
Jul 27, 2018No Action Indicated (NAI)No citations listed
Feb 21, 2018No Action Indicated (NAI)No citations listed
Nov 9, 2015Voluntary Action Indicated (VAI)No citations listed
Sep 26, 2013Voluntary Action Indicated (VAI)No citations listed
Dec 6, 2012Voluntary Action Indicated (VAI)Following/documenting laboratory controls (21 CFR 211.160(a))
Washing and toilet facilities are deficient (21 CFR 211.52)
Samples (various types) representative, identified properly (21 CFR 211.160(b)(1))

Recalls

Newest first. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Nov 19, 2021Class IID-0276-2022Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/325 mg, 100-count bottle, Rx…
Product Mix-up
Oct 26, 2020Class IID-0097-2021Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/325mg 100-count bottles, Rx…
Presence of Foreign Tablet/Capsule: One bottle of Hydrocodone Bitartrate and Acetaminophen Tablets USP 10mg/325 mg contains one Losartan…
Jan 22, 2018Class IIID-0248-2018Oxycodone Hydrochloride Tablets, USP 15 mg, 100 count bottles, Rx only, Manufactured for…
Labeling; Label Error Not Elsewhere Classified; label missing controlled substance CII symbol

FDA record score

12 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.

Counted on Nov 17, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

8 records behind this number
RecordDatePoints x age weightAdds
Inspection classified VAIAug 9, 20246 x 0.63.6
Inspection classified VAISep 15, 20226 x 0.63.6
Class II recall D-0276-2022, this FEI as the recalling firmNov 19, 20214 x 0.62.4
Inspection classified VAIOct 13, 20206 x 0.251.5
Class II recall D-0097-2021, this FEI as the recalling firmOct 26, 20204 x 0.251
Inspection classified VAINov 9, 201510 years or older, so it adds no points0
Inspection classified VAISep 26, 201310 years or older, so it adds no points0
Inspection classified VAIDec 6, 201210 years or older, so it adds no points0

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 17, 2026Newest record Nov 9, 2026Current
Inspection citationsNov 17, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 17, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 17, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 17, 2026Newest record Nov 16, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing Ascent Pharmaceuticals Inc as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Ascent Pharmaceuticals Inc yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
Ascent Pharmaceuticals Inc
Location
Central Islip, NY (US)
Registration Expires
Dec 31, 2027
Operations
ANALYSIS; LABEL; MANUFACTURE; PACK
Source
decrs

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.